0001104659-22-020895.txt : 20220211 0001104659-22-020895.hdr.sgml : 20220211 20220211213450 ACCESSION NUMBER: 0001104659-22-020895 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220209 FILED AS OF DATE: 20220211 DATE AS OF CHANGE: 20220211 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shulman Joseph CENTRAL INDEX KEY: 0001909855 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38223 FILM NUMBER: 22624299 MAIL ADDRESS: STREET 1: C/O RHYTHM PHARMACEUTICALS STREET 2: 222 BERKELEY STREET, SUITE 1200 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001649904 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462159271 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 857-264-4280 MAIL ADDRESS: STREET 1: 222 BERKELEY STREET STREET 2: 12TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: RHYTHM METABOLIC, INC. DATE OF NAME CHANGE: 20150803 4 1 tm226394-6_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-02-09 0 0001649904 RHYTHM PHARMACEUTICALS, INC. RYTM 0001909855 Shulman Joseph C/O RHYTHM PHARMACEUTICALS, INC. 222 BERKELEY STREET, 12TH FLOOR BOSTON MA 02116 0 1 0 0 Chief Technical Officer Restricted Stock Units 2022-02-09 4 A 0 10625 0 A Common Stock 10625 10625 D Stock Option (Right to Buy) 6.80 2022-02-09 4 A 0 63750 0 A 2032-02-08 Common Stock 63750 63750 D Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. /s/ Hunter Smith, Attorney-in-Fact for Joseph Shulman 2022-02-11